The US Food and Drug Administration (FDA) has approved a new software upgrade for Abbott's Infinity deep-brain stimulation (DBS) system used in patients with Parkinson's disease and essential tremor, ...
Parkinson's disease (PD) is the second most common neurodegenerative disorder, primarily characterized by motor dysfunction. Its pathological hallmark is the abnormal aggregation of α-synuclein (α-syn ...
An investigational deep brain stimulation (DBS) system provides continuous, remote monitoring of brain activity in patients with Parkinson's disease (PD) as they go about their everyday activities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results